Related Experiment Videos
Ovarian sertoliform endometrioid carcinoma
1Institute of Clinical Pathology, Geneva Cantonal University Hospital, Switzerland.
Virchows Archiv : an International Journal of Pathology
|January 1, 1995
Summary
Sertoliform endometrioid carcinoma (SEC) is a rare ovarian cancer in post-menopausal women. Immunohistochemistry for anti-epithelial membrane antigen aids in its diagnosis, distinguishing it from other ovarian tumors.
Area of Science:
- Gynecologic Pathology
- Oncology
- Reproductive Endocrinology
Background:
- Sertoliform endometrioid carcinoma (SEC) is an exceptionally rare ovarian neoplasm.
- It predominantly affects post-menopausal patients, presenting diagnostic challenges.
Observation:
- A case of a 71-year-old female with a large (25 cm) right ovarian mass is presented.
- Histological examination revealed SEC with endometrioid and clear cell differentiation.
Findings:
- SEC must be differentiated from Sertoli cell tumors and Sertoli-Leydig cell tumors, which occur in younger individuals.
- The study highlights the diagnostic value of anti-epithelial membrane antigen (EMA) in identifying SEC.
Implications:
- Accurate diagnosis of SEC is crucial for appropriate patient management.
- Further research into EMA's role may refine diagnostic protocols for rare ovarian neoplasms.